• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Daclizumab: DECIDE trial update

October 8, 2015  

Sequencing MS therapies: 2 studies

August 19, 2015  

Does psoriasis improve MS outcomes?

August 19, 2015  

Natalizumab in progressive MS: Phase II results

July 8, 2015  

ACTH revisited: melanocortins and MS

June 11, 2015  

Use of high-efficacy agents in MS: Updated data from AAN 2015

June 3, 2015  

Efficacy and effectiveness of first-line oral medications in MS

May 21, 2015  

Optimizing patient assessment in MS: NEDA and beyond

March 12, 2015  

NEUROSOUND: CHARCOT 2014 HIGHLIGHTS

February 11, 2015  

Pharma sales projected to top $1 trillion

February 4, 2015  
Previous
30
31
32
33
34
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions